Nation-state actors treat pharma like critical infrastructure targeting formulation data, synthesis routes, and clinical IP with patience and precision. Learn why standard pen testing misses this threat and what adversary simulation reveals instead.

R&D and GxP regulated environments have different risk profiles, compliance requirements, and testing constraints. Learn why a single unified pen test scope fails both and how to run dual-scope engagements efficiently.

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.